News

16

May, 2022

Capacitating the future of research in paediatric HIV

Tags: ,

By design, capacity building is a fundamental part of the UNIVERSAL project. The aim of the project's capacity building activities are to improve the ability of African and European young investigators in designing and conducting clinical trials. As such, the project conducted a Training Needs Assessment (TNA) from March 17th to June 21st 2021 among 108 African early career researchers from Cameroon, Mali, Senegal, Uganda and Zimbabwe who are involved in the project (see fig 1 below). A TNA is the process of collecting and analysing data to determine what [...]
READ MORE

23

Mar, 2022

Dolutegravir dosing for children with HIV weighing less than 20 kg

Tags: ,

The results of an ODYSSEY pharmacokinetic sub-study investigating dolutegravir (DTG) based antiretroviral (ARV) treatments for children weighing 3 to less than 20kg have recently been published in The Lancet HIV as an Open Access article. DTG has been available for treating HIV in adults globally for many years with paediatric formulations only developed in recent years. Very little pharmacokinetic data were available in young children when the ODYSSEY trial was opened to young children. With this in mind, the team nested a sub-study to evaluate pharmacokinetics and safety and confirm the optimal […]

READ MORE

14

Mar, 2022

WHO Paediatric ARV dosing dashboard

Tags: , ,

The WHO have developed a Paediatric ARV dosing dashboard which aims to support health care workers, researchers and policy makers in decisions around ARV dosing for children. It includes a dosing tool to assist in selecting the correct dose for infants, children and adolescents less than 18 years old, background information to support WHO paediatric weight-band dosing recommendations for ARV drugs, and a tool for researchers who want to investigate various ARV dosages and calculate the expected drug exposure in children relative to adult targets after administration of various doses. […]

READ MORE

30

Dec, 2021

Once-daily DTG more effective in treating HIV in children

Tags: ,

The ODYSSEY trial’s final paper Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children has been published in the New England Journal of Medicine. ODYSSEY, sponsored by Penta and funded by ViiV Healthcare, is the first randomised controlled trial to compare the efficacy and safety of dolutegravir-based regimens to non-dolutegravir-based standard-of-care regimens in children and adolescents. Dolutegravir (DTG) is a drug shown to be highly effective and safe in treating HIV in adults, and ODYSSEY, enrolling more than 700 children from Uganda, South Africa, Zimbabwe, Thailand, UK, Germany, […]

READ MORE

15

Dec, 2021

Ethical youth engagement in the HIV response

Tags: ,

Penta youth in collaboration with IAS, have organised a webinar taking place on Thursday, 16 December at 12pm CET (GMT+1) on the theme Invest in our future: How to walk the talk of ethical Youth engagement in the HIV response. The objectives of the webinar are to showcase best practices for youth participation within the HIV sector, to highlight the current gaps in proactive responses to youth participation models and insight, and to discuss the importance of ethical youth engagement being backed by policies co-produced by young people and key […]

READ MORE

7

Dec, 2021

REACH project published in CORDIS

Tags: ,

We are proud to announce that the REACH project’s Result in Brief article, Reducing infectious disease in mothers and children in Russia, has been uploaded on the CORDIS website. This is a great opportunity to share our work, with the rest of the world and will ensure that our study results, when available, are available to many. None of what REACH has achieved would have been possible without the collaborative effort of our partners in Europe and the Russian Federation. Through the joint commitment of our members, the REACH project […]

READ MORE

1

Dec, 2021

World AIDS Day 2021: How paediatric HIV has changed in the last 30 years

Tags: ,

It takes a community of people working together to achieve the results we are looking for: eradication HIV in children   The paediatric HIV pandemic has changed from when researchers first began investigating HIV in children to where we stand today. The burden of perinatal infections, however, remains high. Perinatal infections occur when a pregnant person living with HIV passes HIV to her baby either during pregnancy, delivery or through breastfeeding. Despite unprecedented advances in the prevention of perinatal infections (including those occurring through breastfeeding) utilizing maternal ART and infant […]

READ MORE

19

Nov, 2021

In Memory of Dr Scott M. Hammer

Tags:

With a great sadness I learnt today that Scott passed away. The IAS obituary says everything about him as a great scientist. I just would like to remember him as a very good friend who cared about children throughout his professional life. In 2006 we chaired together the WHO working group to develop the guidelines for antiretroviral  therapy “Toward universal access”. Scott has been mentoring me in an unforgettable way ! Carlo Giaquinto on behalf of Penta ______________________________________________________________________________________ The IAS-USA is deeply saddened by the passing of Dr Scott M. […]

READ MORE

29

Oct, 2021

ODYSSEY trial wins 2021 Hector Award

Tags: , ,

It was announced at the 8th European AIDS Conference that Angela Colbers and David Burger received the Hector Research Award in HIV 2021 in clinical and/or epidemiological science on behalf of the ODYSSEY trial team! The winning paper Simplified dolutegravir dosing for children with HIV weighting 20kg or more pharmacokinetic and safety substudies of the multicentre randomised ODYSSEY trial, can be found here. Congratulations to the entire study team and thank you to all the families and children who participated in the ODYSSEY trial. Sponsored by Penta and funded by […]

READ MORE

7

Sep, 2021

Project New Generation (PNG+)

Tags: , ,

Project New Generation (PNG+) are a group of young people living with HIV who serve as the voice of the youth involved in the REACH study. Made up of two groups, one based in St. Petersburg and the other in Irkutsk, and supported by local psychologists, this group of 20 bring to the forefront, issues that the youth living with HIV are directly affected by. The activities of PNG+ are led by the Penta PPI team. Pre-COVID-19, the PPI team held a number of in-person meetings with the young people, […]

READ MORE
NEWSLETTER

We would like to update you on our recent activities